Guggenheim Reiterates Buy on Aralez Pharma (ARLZ) Following Yosprala Approval
- Top 10 News for 9/19 - 9/23: Twitter on the Auction Block; Allergan Bolsters NASH Effort; Microsoft Returns Value
- Wall Street falls as energy lags; shares post gains on week
- Rumored Forever, Twitter (TWTR) May Have Finally Put the 'For Sale' Sign Up
- Facebook (FB) Shares Under Pressure on Reports Video Ad Metrics Were Artificially Inflated
- Brookfield Infrastructure (BIP)-Led Consortium to Take Controlling Stake in Petrobras' (PBR) NTS for $5.2B
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Guggenheim reiterated a Buy rating and $12.00 price target on Aralez Pharmaceuticals (NASDAQ: ARLZ) following the approval of Yosprala and the recent acquisition of Zontivity. Yosprala will complement ARLZ's Fibricor, which is another CV drug that ARLZ already markets, and Zontivity, which ARLZ recently acquired.
Analyst Louise Chen commented, "Today's approval of Yosprala and the recent acquisition of Zontivity underscore our positive investment thesis. We continue to believe that there is upside to consensus expectations and this could come from: 1) ARLZ's approved products; 2) The company's pipeline; as well as 3) Business develop, which ARLZ has publicly stated will be focused on CV and Pain. We believe Yosprala could reach sales of $200MM+ by '22. Additionally, we think ARLZ will be a successful consolidator of assets with its strong balance sheet, experienced management team, and low tax rate."
Shares of Aralez Pharmaceuticals closed at $5.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Partners Remains Bullish on Acadia Healthcare (ACHC); CMA Extends Acquisition Assesment Deadline Through Nov
- Canaccord Genuity Cuts Price Target on Nike (NKE) to $52 Ahead of 1Q Report
- Credit Suisse Upgrades Transocean (RIG) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesDefinitive Agreement, Louise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!